Surmodics, Inc. SRDX
Set alert
As of Nov 25, 9:30 AM ET
- YTD
- +8.54%
- 1 year
- +9.50%
- Open
- 42.98
- Prev close
- 42.98
- Mkt cap
- 564.90M
- Vol
- 5.34M
- Avg vol
- 203.31K
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 42.98
- High
- 42.98
- Forward P/E
- 141.14
- Beta
- 1.20
- Short ratio
- 1.62
- Inst. own
- 84.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 6, 2025
- 50-d avg
- 38.89
- 200-d avg
- 37.09
- 1y target
- 43.00
2Y chart
Events in this range
- Feb 1, 2024Earnings: 0; estimate -0.35; surprise —%
- May 1, 2024Earnings: 0.07; estimate -0.36; surprise 119.44%
- May 29, 2024Downgrade: Needham · Buy → Hold
- May 29, 2024Downgrade: Sidoti & Co. · Buy → Neutral
- May 29, 2024Downgrade: Lake Street · Buy → Hold
- May 30, 2024Downgrade: Barrington Research · Outperform → Market Perform
- Jul 31, 2024Earnings: -0.27; estimate -0.31; surprise 12.9%
- Aug 5, 2024Rating: Needham · — → Hold
- Nov 6, 2024Earnings: -0.13; estimate -0.27; surprise 51.85%
- Nov 7, 2024Rating: Needham · — → Hold
- Feb 6, 2025Earnings: —; estimate -0.08; surprise —%
Signals (67)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| RSI: Overbought | Nov 11, 2025 | 11 months ago |
| RSI: Oversold | Oct 23, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 17, 2025 | 1 year ago |
| RSI: Oversold | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Sep 4, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 11, 2025 | 1 year ago |
| RSI: Overbought | Aug 11, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 25, 2025 | 1 year ago |
| RSI: Overbought | Jul 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| SMA: Bullish | May 28, 2025 | 1 year ago |
| SMA: Bearish | May 23, 2025 | 1 year ago |
| SMA: Bullish | May 19, 2025 | 1 year ago |
| MACD: Buy Signal | May 14, 2025 | 1 year ago |
| MACD: Sell Signal | May 5, 2025 | 1 year ago |
| SMA: Bearish | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| RSI: Oversold | Jan 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 28, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 27, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| RSI: Oversold | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 7, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 17, 2024 | 1 year ago |
| RSI: Overbought | Dec 5, 2024 | 1 year ago |
| SMA: Bullish | Nov 15, 2024 | 1 year ago |
| SMA: Bearish | Nov 13, 2024 | 1 year ago |
| SMA: Bullish | Nov 12, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 6, 2024 | 1 year ago |
| MACD: Sell Signal | Oct 25, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 9, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 26, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 10, 2024 | 2 years ago |
| RSI: Oversold | Sep 3, 2024 | 2 years ago |
| RSI: Oversold | Aug 13, 2024 | 2 years ago |
| SMA: Bearish | Aug 2, 2024 | 2 years ago |
| RSI: Overbought | Jul 16, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 13, 2024 | 2 years ago |
| RSI: Overbought | May 29, 2024 | 2 years ago |
| RSI: Overbought | May 17, 2024 | 2 years ago |
| SMA: Bullish | May 1, 2024 | 2 years ago |
| RSI: Overbought | May 1, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 23, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 22, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 27, 2024 | 2 years ago |
| RSI: Oversold | Mar 18, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 5, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 23, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 16, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 14, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 29, 2024 | 2 years ago |
Key statistics
- Market cap
- 564.90M
- Enterprise value
- 553.45M
- Trailing P/E
- 0.00
- Forward P/E
- 141.14
- PEG ratio
- 0.00
- Price / sales
- 4.48
- Price / book
- 4.72
- EPS (TTM)
- -0.82
- Beta
- 1.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -9.16%
- Revenue (TTM)
- 126.08M
- Revenue growth
- 18.80%
- Free cash flow
- 7.61M
- Total cash
- 40.11M
- Total debt
- 29.55M
- Return on equity
- -9.67%
- Shares outstanding
- 14.29M
- Short % of float
- 3.18%
- 50-day average
- 38.89
- 200-day average
- 37.09
Analyst view
Consensus: none
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 6, 2025
Expected Feb 6, 2025. Consensus EPS estimate -0.11667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 6, 2025 | Dec 1, 2024 | -0.08 | — | — | — |
| Nov 6, 2024 | Sep 1, 2024 | -0.27 | -0.13 | +0.14 | +51.85% |
| Jul 31, 2024 | Jun 1, 2024 | -0.31 | -0.27 | +0.04 | +12.90% |
| May 1, 2024 | Mar 1, 2024 | -0.36 | 0.07 | +0.43 | +119.44% |
| Feb 1, 2024 | Dec 1, 2023 | -0.35 | 0.00 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.16 | 0.53 | +0.37 | +231.25% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Needham | reit | — | Hold |
| Aug 5, 2024 | Needham | reit | — | Hold |
| May 30, 2024 | Barrington Research | down | Outperform | Market Perform |
| May 29, 2024 | Lake Street | down | Buy | Hold |
| May 29, 2024 | Sidoti & Co. | down | Buy | Neutral |
| May 29, 2024 | Needham | down | Buy | Hold |
About Surmodics, Inc.
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- surmodics.com
News
- Brokerages Set Surmodics, Inc. (NASDAQ:SRDX) Target Price at $43.00
- Medtech Integer Could Be More Valuable As A Private Company - Activist Investor Urges Strategic Review
- Groupe la Francaise Sells 33,700 Shares of Surmodics, Inc. $SRDX
- Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
- Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
- PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday
- US Stocks Mixed; Sea Shares Gain After Q3 Results
- Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
Your note
Sign in to keep a note on SRDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARENS TIMOTHY J. | Chief Financial Officer | Sale | Nov 25, 2024 | 70,350 |
| BEDOYA JOSE H | Director | Stock Award(Grant) | Feb 7, 2024 | 28,957 |
| DANTZKER DAVID R | Director | Stock Award(Grant) | Feb 7, 2024 | 39,124 |
| HEINE LISA WIPPERMAN | Director | Stock Award(Grant) | Feb 7, 2024 | 13,453 |
| KALICH RONALD B SR | Director | Stock Award(Grant) | Feb 7, 2024 | 38,278 |
| KNIGHT SUSAN E | Director | Stock Award(Grant) | Feb 7, 2024 | 35,148 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.18% | 1,169,670 | 46.23M | Sep 29, 2024 |
| Alliancebernstein L.P. | 7.28% | 1,040,430 | 41.12M | Sep 29, 2024 |
| Beryl Capital Management LLC | 6.92% | 988,904 | 39.08M | Sep 29, 2024 |
| Vanguard Group Inc | 5.62% | 803,508 | 31.75M | Sep 29, 2024 |
| Morgan Stanley | 5.27% | 752,706 | 29.75M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 4.46% | 637,698 | 25.20M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 422,044 | 16.68M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.45% | 350,868 | 13.87M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.54% | 220,432 | 8.71M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.98% | 140,668 | 5.56M | Aug 30, 2024 |
| DFA U.S. Small Cap Series | 0.83% | 118,517 | 4.68M | Jul 30, 2024 |
| Gabelli ABC Fund | 0.69% | 99,000 | 3.91M | Sep 29, 2024 |